A total of 507 patients with a CLDN18.2-positive but HER2-negative status with advanced unresectable or metastatic gastric or GEJ adenocarcinoma were blindly assigned to either group. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.